Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 173

1.

Imaging of meningeal inflammation should become part of the routine MRI protocol - No.

Wattjes MP, Killestein J.

Mult Scler. 2018 Sep 4:1352458518799642. doi: 10.1177/1352458518799642. [Epub ahead of print] No abstract available.

PMID:
30179073
2.

gMS-Classifier1 does not predict disability progression in multiple sclerosis.

van Rossum JA, Killestein J, Villar LM, Riskind PN, Freedman MS, Teunissen C.

Mult Scler. 2018 Aug 31:1352458518798048. doi: 10.1177/1352458518798048. [Epub ahead of print] No abstract available.

PMID:
30168749
3.

Acute syphilitic meningitis in an HIV-infected patient.

Wagemakers A, Hepp D, Killestein J, Peferoen L, Ang W.

IDCases. 2018 Jul 7;13:e00423. doi: 10.1016/j.idcr.2018.e00423. eCollection 2018.

4.

Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.

Wijburg MT, Warnke C, Barkhof F, Uitdehaag BMJ, Killestein J, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2018 Aug 12. pii: jnnp-2018-318261. doi: 10.1136/jnnp-2018-318261. [Epub ahead of print]

PMID:
30100552
5.

Information processing speed in multiple sclerosis: Relevance of default mode network dynamics.

van Geest Q, Douw L, van 't Klooster S, Leurs CE, Genova HM, Wylie GR, Steenwijk MD, Killestein J, Geurts JJG, Hulst HE.

Neuroimage Clin. 2018 May 15;19:507-515. doi: 10.1016/j.nicl.2018.05.015. eCollection 2018.

6.

Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.

Hagens MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Ciccarelli O, Gasperini C, Lukas C, Wattjes MP, Barkhof F; MAGNIMS Study Group.

Neurology. 2018 Jul 17;91(3):e249-e257. doi: 10.1212/WNL.0000000000005825. Epub 2018 Jun 20.

7.

Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, de Vos M, Warnke C, Uitdehaag BMJ, Barkhof F, Killestein J, Wattjes MP.

JAMA Neurol. 2018 Jul 1;75(7):827-833. doi: 10.1001/jamaneurol.2018.0094.

PMID:
29532061
8.

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 5;5(1):e424. doi: 10.1212/NXI.0000000000000424. eCollection 2018 Jan.

9.

Deep gray matter volume loss drives disability worsening in multiple sclerosis.

Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group.

Ann Neurol. 2018 Feb;83(2):210-222. doi: 10.1002/ana.25145. Epub 2018 Feb 6.

10.

Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study.

Hagens MH, Burggraaff J, Kilsdonk ID, Ruggieri S, Collorone S, Cortese R, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Wuerfel J, Ciccarelli O, Gasperini C, Lukas C, Rovira A, Barkhof F, Wattjes MP; MAGNIMS Study Group.

Mult Scler. 2018 Jan 1:1352458517751647. doi: 10.1177/1352458517751647. [Epub ahead of print]

PMID:
29327668
11.

Gray matter networks and cognitive impairment in multiple sclerosis.

Rimkus CM, Schoonheim MM, Steenwijk MD, Vrenken H, Eijlers AJ, Killestein J, Wattjes MP, Leite CC, Barkhof F, Tijms BM.

Mult Scler. 2018 Jan 1:1352458517751650. doi: 10.1177/1352458517751650. [Epub ahead of print]

PMID:
29320933
12.

Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?

Sestito C, Brevé JJP, van Eggermond MCJA, Killestein J, Teunissen CE, van Rossum J, Wilhelmus MMM, Drukarch B, van den Elsen PJ, van Dam AM.

J Neuroinflammation. 2017 Dec 21;14(1):257. doi: 10.1186/s12974-017-1035-y.

13.

Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS.

Bruinsma IB, van Dijk M, Bridel C, van de Lisdonk T, Haverkort SQ, Runia TF, Steinman L, Hintzen RQ, Killestein J, Verbeek MM, Teunissen CE, de Jong BA.

J Neuroinflammation. 2017 Dec 4;14(1):235. doi: 10.1186/s12974-017-1006-3.

14.

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.

Wattjes MP, Wijburg MT, van Eijk J, Frequin S, Uitdehaag BMJ, Barkhof F, Warnke C, Killestein J; Dutch-Belgian Natalizumab-Associated PML Study Group.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):535-541. doi: 10.1136/jnnp-2017-316886. Epub 2017 Nov 15.

PMID:
29142146
15.

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.

Dekker I, Sombekke MH, Witte BI, Geurts JJ, Barkhof F, Uitdehaag BM, Killestein J, Wattjes MP.

Mult Scler. 2018 Apr;24(4):481-490. doi: 10.1177/1352458517736147. Epub 2017 Nov 6.

16.

Response to "Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".

van Kempen ZL, Rispens T, Killestein J.

Mult Scler. 2018 May;24(6):822-823. doi: 10.1177/1352458517734073. Epub 2017 Oct 9. No abstract available.

17.

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.

Leurs CE, van Kempen ZL, Dekker I, Balk LJ, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2018 Oct;24(11):1453-1460. doi: 10.1177/1352458517726381. Epub 2017 Aug 21.

18.

Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets.

Best MG, Sol N, In 't Veld SGJG, Vancura A, Muller M, Niemeijer AN, Fejes AV, Tjon Kon Fat LA, Huis In 't Veld AE, Leurs C, Le Large TY, Meijer LL, Kooi IE, Rustenburg F, Schellen P, Verschueren H, Post E, Wedekind LE, Bracht J, Esenkbrink M, Wils L, Favaro F, Schoonhoven JD, Tannous J, Meijers-Heijboer H, Kazemier G, Giovannetti E, Reijneveld JC, Idema S, Killestein J, Heger M, de Jager SC, Urbanus RT, Hoefer IE, Pasterkamp G, Mannhalter C, Gomez-Arroyo J, Bogaard HJ, Noske DP, Vandertop WP, van den Broek D, Ylstra B, Nilsson RJA, Wesseling P, Karachaliou N, Rosell R, Lee-Lewandrowski E, Lewandrowski KB, Tannous BA, de Langen AJ, Smit EF, van den Heuvel MM, Wurdinger T.

Cancer Cell. 2017 Aug 14;32(2):238-252.e9. doi: 10.1016/j.ccell.2017.07.004.

19.

Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS.

Killestein J, Leurs CE, Hoogervorst ELJ, van Eijk J, Mostert JP, van den Eertwegh AJM, Uitdehaag BMJ.

Neurology. 2017 Aug 29;89(9):970-972. doi: 10.1212/WNL.0000000000004293. Epub 2017 Aug 2. No abstract available.

PMID:
28768850
20.

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.

van Kempen ZLE, Leurs CE, de Vries A, Vennegoor A, Rispens T, Wattjes MP, Killestein J.

Eur J Neurol. 2017 Sep;24(9):1196-1199. doi: 10.1111/ene.13355. Epub 2017 Jul 14.

PMID:
28707781

Supplemental Content

Loading ...
Support Center